Equities researchers at HC Wainwright began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a research report issued on Thursday, Briefing.com reports. The brokerage set a “buy” rating and a $18.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 294.74% from the stock’s current price.
VNDA has been the topic of several other research reports. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, October 24th. They issued a “hold” rating on the stock. Cantor Fitzgerald raised their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st.
View Our Latest Research Report on VNDA
Vanda Pharmaceuticals Stock Down 2.8 %
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million for the quarter. As a group, equities analysts expect that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Vanda Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its stake in Vanda Pharmaceuticals by 18.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 2,509 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares in the last quarter. Susquehanna Fundamental Investments LLC boosted its stake in Vanda Pharmaceuticals by 2.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock worth $1,625,000 after buying an additional 5,994 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in Vanda Pharmaceuticals during the second quarter worth $39,000. Institutional investors and hedge funds own 88.14% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
- Five stocks we like better than Vanda Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- Applied Materials vs ASML: Which is the Best Chip Stock to Own?
- Earnings Per Share Calculator: How to Calculate EPS
- Top Bill Gates Stock Picks Every Investor Should Know About
- Ride Out The Recession With These Dividend KingsĀ
- Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.